Category Archives: beta-thalassemia

Beta thalassemia is a blood disorder that reduces the production of hemoglobin. Hemoglobin is the iron-containing protein in red blood cells that carries oxygen to cells throughout the body.

In people with beta thalassemia, low levels of hemoglobin lead to a lack of oxygen in many parts of the body. Affected individuals also have a shortage of red blood cells (anemia), which can cause pale skin, weakness, fatigue, and more serious complications. People with beta thalassemia are at an increased risk of developing abnormal blood clots.

Beta thalassemia is classified into two types depending on the severity of symptoms: thalassemia major and thalassemia intermedia. Thalassemia major is more severe.

New Small Business Grant from NIH Heart, Lung and Blood Institute

Phoenicia scientists were recently awarded a Phase 2 Small Business Grant from the NIH NHLBI (“Development of a Clinical Hemoglobin Modulator” R42 HL-110727-02) to support clinical development of PB-04, the lead drug candidate for the treatment of β-thalassemia and sickle cell disease

Phoenicia’s Lead Drug for Hemoglobinopathies selected by NIH-TRND Program

image1445 Phoenicia’s lead drug candidate for the treatment of β-thalassemia and sickle cell disease (PB-04), was recently selected as a project within the Therapeutics for Rare and Neglected Diseases program at the NIH’s National Center for Advancing Translational Sciences. Through our collaboration with TRND researchers, we gain access to preclinical drug development expertise. The goal of the TRND program is to work with collaborators to advance potential treatments to human clinical trials.